对DLBCL中可能的HDAC抑制剂耐药的新见解——Havas等人对“定义对HDAC选择性抑制剂的细胞反应表明,需要有效靶向HDAC3来引发细胞毒性并克服naïve弥漫性大B细胞淋巴瘤中泛hdaci的耐药”的评论。

IF 5 2区 医学 Q2 Medicine
Tobias Kiesslich , Christian Mayr , Dino Bekric , Daniel Neureiter
{"title":"对DLBCL中可能的HDAC抑制剂耐药的新见解——Havas等人对“定义对HDAC选择性抑制剂的细胞反应表明,需要有效靶向HDAC3来引发细胞毒性并克服naïve弥漫性大B细胞淋巴瘤中泛hdaci的耐药”的评论。","authors":"Tobias Kiesslich , Christian Mayr , Dino Bekric , Daniel Neureiter","doi":"10.1016/j.tranon.2023.101820","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"44 ","pages":"Article 101820"},"PeriodicalIF":5.0000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523323002061/pdfft?md5=92c597a36046d1538f250d75caac3162&pid=1-s2.0-S1936523323002061-main.pdf","citationCount":"0","resultStr":"{\"title\":\"New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.\",\"authors\":\"Tobias Kiesslich , Christian Mayr , Dino Bekric , Daniel Neureiter\",\"doi\":\"10.1016/j.tranon.2023.101820\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":48975,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"44 \",\"pages\":\"Article 101820\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2023-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1936523323002061/pdfft?md5=92c597a36046d1538f250d75caac3162&pid=1-s2.0-S1936523323002061-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1936523323002061\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523323002061","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

摘要不可用
本文章由计算机程序翻译,如有差异,请以英文原文为准。
New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.40
自引率
2.00%
发文量
314
审稿时长
54 days
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信